Volatility and Volume movement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Guggenheim Remains Positive on Valeant (VRX) post Q3: 'In the Kitchen Sink, but Not Down the Drain'
November 8, 2016 10:35 AM ESTGuggenheim analyst Louise Chen weighed in on Valeant Pharmaceuticals (NYSE: VRX) after the company reported, as expected, a 3Q16 miss and lowered its '16 EPS guidance.
Chen commented, "VRX has noted since its 1Q16 call that the business should start to recover in 2H16. Evidence of this was demonstrated in 3Q16 as VRX reported sequential improvements in sales and EBITDA throughout the year. Therefore, despite the miss and... More
Valeant Pharma (VRX) Sees Solid Bounce Off Morning Lows
November 8, 2016 10:16 AM ESTValeant Pharma (NYSE: VRX) has moved solidly off morning lows but remains down 20.5% to $15.21. Shares were down as much as 28% to $13.77 earlier.
The bounce could be short covering.
... More